Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: A break of intestinal insulin resistance?

Journal of Hepatology

Volumn 52, Issue 6, 2010, Pages 952-953

  Rudovich, Natalia N ^a,b   Weickert, Martin O ^a,b,d,e   Machann, Juergen ^c   Pfeiffer, Andreas F H ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; EZETIMIBE; PLACEBO; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; GENE CONTROL; GLYCEMIC INDEX; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; LIPID DIET; LIVER FIBROSIS; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL;

ACARBOSE; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 77952545900     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.004     Document Type: Letter

References (8)

1. Nozaki Y., Fujita K., Yoneda M., Wada K., Shinohara Y., Takahashi H., et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 51 (2009) 548-556
2. Qureshi K., and Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 14; 13 (2007) 3540-3553
3. Abid A., Taha O., Nseir W., Farah R., Grosovski M., and Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 51 (2009) 918-924
4. Valtuena S., Pellegrini N., Ardigo D., Del Rio D., Numeroso F., Scazzina F., et al. Dietary glycemic index and liver steatosis. Am J Clin Nutr 84 (2006) 136-142
5. Rudovich N., Ernst A., Pivovarova O., Traberth A., Bergmann A., and Pfeiffer A.F.H. Acarbose increases atrial natriuretic peptide levels in subjects with metabolic syndrome: a novel mechanism of cardiovascular protection. J Diab. 1 (2009) A42
6. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
7. Jeon T.I., Zhu B., Larson J.L., and Osborne T.F. SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice. J Clin Invest 118 (2008) 3693-3700
8. Hsieh J., Hayashi A.A., Webb J., and Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl 9 (2008) 7-13